Halozyme Therapeutics Inc - Company Profile
Powered by 
All the sales intelligence you need on Halozyme Therapeutics Inc in one solution.
- Save hours of research time with a comprehensive
Sales Intelligence Solution.
- Understand how Halozyme Therapeutics Inc fits into your total
addressable market and Ideal Customer Profile.
- Gain competitive edge with triggers that tell you
when and how to engage with Halozyme Therapeutics Inc.
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
Halozyme Therapeutics Inc (Halozyme) is a biotechnology company that develops and commercializes novel recombinant human enzymes for enhancing the delivery of biologics and drugs. The company’s marketed product, Hylenex, is a branded recombinant formulation of rHuPH20, which facilitates the administration of subcutaneous fluid with improved hydration, absorption and dispersion of other injected drugs and enhanced resorption of radiopaque agents in subcutaneous urography. The company also offers proprietary Enhanze, a drug-delivery technology built on its patented recombinant human hyaluronidase enzyme, rHuPH20. It works in partnership with Pfizer, Roche and Janssen, among others, to advance the treatment of various types of cancers. Halozyme is headquartered in San Diego, California, the US
Headquarters
United States of America
Address
12390 El Camino Real, San Diego, California, 92130
Website
www.halozyme.com
Telephone
1 302 6587581
No of Employees
423
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
HALO (NASD)
Revenue (2024)
$1.4B
37.6%
(2024 vs 2023)
EPS
XYZ
Net Income (2024)
XYZ
-28.6%
(2024 vs 2023)
Market Cap*
$9.4B
Net Profit Margin (2024)
XYZ
-48.1%
(2024 vs 2023)
* As of and is in US$
Halozyme Therapeutics Inc premium industry data and analytics
Products and Services
| Products | Brands |
|---|---|
| Hylenex Recombinant | Hylenex |
| Enhanze Drug Delivery Technology | Enhanze |
| TLANDO Testosterone Undecanoate | Tlando |
| XYZ | XYZ |
| XYZ | XYZ |
| XYZ | XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2026 | Contracts/Agreements | In May, the company and GSK entered into an agreement to license Halozyme's ENHANZE drug-delivery technology for the development and potential commercialization of subcutaneous formulations for multiple oncology targets. |
| 2026 | Contracts/Agreements | In January, the company entered into a license agreement with Skye Bioscience, Inc. for the license of Halozyme's ENHANZE drug delivery technology for the development and potential commercialization of a subcutaneous formulation of nimacimab for the treatment of obesity. |
| 2026 | Acquisitions/Mergers/Takeovers | In January, the company acquired Surf Bio Inc, a biopharmaceutical company. |
Competitor Comparison
| Key Parameters | Halozyme Therapeutics Inc | Pfizer Inc | AbbVie Inc | Perrigo Co Plc | West Pharmaceutical Services Inc |
|---|---|---|---|---|---|
| Headquarters | United States of America | United States of America | United States of America | Ireland | United States of America |
| City | San Diego | New York City | North Chicago | Dublin | Exton |
| State/Province | California | New York | Illinois | Dublin | Pennsylvania |
| No. of Employees | 423 | 75,000 | 57,000 | 8,100 | 10,800 |
| Entity Type | Public | Public | Public | Public | Public |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Jeffrey W. Henderson | Chairman | Executive Board | 2022 | 61 |
| Helen I. Torley | Director; Chief Executive Officer; President | Executive Board | 2014 | 63 |
| Darren Snellgrove | Chief Financial Officer | Senior Management | 2026 | - |
| Cortney Caudill | Senior Vice President; Chief Operating Officer | Senior Management | 2023 | - |
| Rhys de Callier | Chief Strategy Officer | Senior Management | 2025 | - |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer